Phase I clinical trial of newly developed antigen peptide vaccine for advanced esophageal cancer
Not Applicable
- Conditions
- Advanced esophageal squamous cell carcinoma patietns treated with standart therapy includingn surgery, chemotherapy and radiotherapy, and all these treatments were failed.
- Registration Number
- JPRN-UMIN000004662
- Lead Sponsor
- Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
Pregnancy Lactating woman Severe bleeding tendency uncontroled infection concomitant treatment with steroids patients who are judged inappropriate for eligibility by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety and adverse event of the peptide vaccine
- Secondary Outcome Measures
Name Time Method